Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor-derived CD19/CD22 CAR Therapy and Allo-HSCT in r/r B-ALL
NCT06326008Phase 1Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Mar 2026
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Beijing Gaobo Hospital. Primary endpoints: Dose-limiting toxicity at 43 days and Adverse events at 120 days. Started Mar 2026; status: recruiting.
02
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06326008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06326008.